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Objective. Streptococcal bacteremia occurs during hematopoietic cell transplantation (HCT), and treatment of active oral
disease may reduce this risk. The objective of this study was to determine the type, number, and costs of pre-transplantation
dental procedures in this population.
Study Design. Data were collected retrospectively from the records of patients who were to undergo HCT. The type, number,
and costs of dental procedures were determined based on median charges of MassHealth (the Medicaid program in
Massachusetts) and also on the median “usual and customary” fees charged by dentists in Massachusetts.
Results. A total of 405 patients were evaluated. There were 243 men (60%) and 162 women, with a median age of 53 years.
The median and average costs (in US dollars) of dental treatment before HCT were $275 and $384, respectively, for patients
covered by MassHealth and $368 and $522, respectively, for those with private insurance, adjusted to 2012 levels.
Conclusions. Dental evaluation before HCT is an economical way for patients to minimize the risk of localized infection and
possibly reduce the risk of bacteremia that may prolong the length of hospitalization. (Oral Surg Oral Med Oral Pathol Oral
Radiol 2014;117:59-66)Hematopoietic cell transplantation (HCT) is often
used to treat hematologic malignancies including
lymphoma, leukemia, multiple myeloma, aplastic
anemia, and other bone marrow failure syndromes.1,2
Myeloablative regimens lead to a predictable period of
profound neutropenia and frequently result in the loss
of mucosal epithelial integrity (ulcerative mucositis),
which can permit the entry of organisms from the
digestive tract into the blood, resulting in bacteremia.3
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http://dx.doi.org/10.1016/j.oooo.2013.08.021The oral cavity is host to many types of bacteria,
including alpha-hemolytic streptococcal species,
particularly viridans streptococci. These organisms are
associated with bacteremia and sepsis in patients who
undergo induction chemotherapy and myeloablative
conditioning in preparation for HCT.4-10 Before 1990,
most bloodstream infections in neutropenic patients
were caused by gram-negative rods such as Escherichia
coli, Pseudomonas aeruginosa, and Klebsiella species.
However, since 1990 there has been a shift to gram-
positive bacteria such as viridans streptococci.11,12
Approximately 40% of reported cases of sepsis were
attributed to gram-positive cocci, whereas 35% to 62%
were a result of gram-negative rods.13,14 One of the most
important factors contributing to this shift is the use of
ﬂuoroquinolones for the prophylaxis of gram-negative
bacterial infections among patients undergoing
HCT.14,15 The viridans streptococci are typically resis-
tant to these antibiotics, and their use promotes coloni-
zation and likely subsequent bacteremia and sepsis.16
The presence of ulcerative mucositis has been shown to
increase the frequency of viridans streptococcal bacter-
emia 3-fold and the length of hospital stay by 6 days.17Statement of Clinical Relevance
Septicemia results in signiﬁcant morbidity for patients
undergoing hematopoietic cell transplantation. A dental
evaluation is an economical way to prevent septicemia
from an oral source. This study shows that for<$1000,
dental needs can be met in >88% of patients.
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patients not only leads to increased use of antibiotics
but also may result in septic shock and respiratory
distress syndrome and is associated with a mortality
rate of 11% to 26%.8,18-21 Even with empiric antibac-
terial treatment, the mortality rate among patients with
complicated streptococcal bacteremia is high.8
Acute dental abscesses are polymicrobial, and
a combination of facultative anaerobes such as viridans
streptococci and Streptococcus anginosus as well as
strict anaerobes are often identiﬁed.22 The US National
Institutes of Health consensus statement on oral
complications of cancer therapy recognized that “dental
foci” are possible sources of systemic infections that
need to be “eliminated or ameliorated” by extraction or
endodontic therapy.9 To this end, all patients from the
Dana-Farber Cancer Institute scheduled for HCT
undergo a formal off-site dental evaluation by their
community dentist.25 This evaluation consists of a full-
mouth series of intraoral radiographs and a compre-
hensive clinical evaluation. An attending oral medicine
specialist at Brigham and Women’s Hospital reviews
and conﬁrms the ﬁndings and treatment plan, and
treatment is then performed by the patient’s community
or primary dentist.23
Medical insurance carriers may reimburse dentists
for the dental evaluation of patients who need HCT;
however, such carriers usually do not pay for the
resulting prescribed dental treatment, because they
expect the dental insurance carriers to do so. Further-
more, a survey of patients from 25 states performed in
1997 reported that 44.3% of responders did not have
dental insurance.24 Untreated dental disease puts
patients at risk for infection during their hospitalization
for HCT, with attendant morbidity and increased
economic burden.24,25
The objective of this study was to determine the
nature, number, and cost of dental procedures recom-
mended for each patient before HCT to eliminate active
dental disease. The study assessed the median cost per
patient and the overall cost effectiveness of the dental
screening program, in this case in Massachusetts.
PATIENTS AND METHODS
Data for this retrospective study were obtained from the
dental records of patients mailed in by dentists and
evaluated at the Division of Oral Medicine and
Dentistry, Brigham and Women’s Hospital, Boston,
MA, USA, from January 2005 to June 2007. Only
records that had full radiographic and clinical evalua-
tions were included in this study.
Data collected included age, gender, medical diag-
nosis, number of carious lesions, number of defective
restorations, presence of removable prosthesis, previous
endodontic therapy, teeth requiring endodontic therapy,probing depths and periodontal health, degree of plaque
and calculus accumulation, and number of extractions
required. Only the type and number of dental proce-
dures required to treat caries, periodontal disease, and
apical disease from pulp necrosis, as well as to extract
nonrestorable teeth (from extensive caries or severe
periodontal disease), were used in the analysis. The
study was exempted from institutional review board
approval, owing to its retrospective nature.Analysis
Each patient’s dental health care costs were estimated
from the payer’s perspective by multiplying the number
and type of recommended procedures by the average
charges for these services. Two estimates were calcu-
lated for each patient. A low estimate of dental costs
was calculated using average MassHealth dental reim-
bursement in 2012, and a high estimate of dental costs
was calculated using the median dental reimbursement
in 2012 provided by Delta Dental of Massachusetts,
a private dental insurance company serving approxi-
mately 30% of the population of Massachusetts. The
term cost as used throughout this study represents a cost
to the payer and not the fee charged by the dentist.
The cost of restorative treatment was calculated by
surfaces ﬁlled with dental amalgam, unless composite
resin was speciﬁed. Extraction costs were calculated
assuming simple extraction based on the number of
teeth to be removed, unless the patient’s primary dental
provider speciﬁed surgical extraction. To estimate the
threshold of risk of streptococcal bacteremia at which
dental screening and treatment are cost neutral, we
computed the average cost per patient, with and without
dental screening and treatment, for risks of bacteremia
between 0% and 25%. We assumed risk reductions with
dental evaluation and therapy between 25% and 90%.
Based on the previously published literature, we
assumed that patients who developed streptococcal
bacteremia would use 3 additional days of hospitaliza-
tion at a total cost of $14,399.17,24,26 The cost of
hospitalization was obtained by adjusting to 2012 US
dollars using the health care component of the
Consumer Price Index.27RESULTS
A total of 423 charts were reviewed, and 18 charts were
excluded because of incomplete diagnostic criteria such
as radiographs and documentation of ﬁndings. Of the
423 charts, 405 (95.7%) were complete and evaluable.
There were 243 men (60%) and 162 women with
a median age of 53 years (range, 18-72). Additional
demographic data are presented in Table I.
Our protocol requires that patients receive a dental
scaling and prophylaxis within the 3 months preceding
Table I. Demographics and characteristics of the
cohort (n ¼ 405)
Characteristic No.
Median age, years (range) 53 (18-72)
Characteristic No. (%)
Male sex 243 (60)
Underlying diagnosis
Non-Hodgkin lymphoma 98 (24.2)
Acute myelogenous
leukemia
80 (19.8)
Multiple myeloma 67 (16.5)
Hodgkin lymphoma 54 (13.3)
Myelodysplastic syndrome 32 (7.9)
Acute lymphocytic
leukemia
25 (6.2)
Chronic lymphocytic
leukemia
14 (3.5)
Chronic myelogenous
leukemia
13 (3.2)
Other 22 (5.4)
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majority of patients had not had a scaling and
prophylaxis performed within the previous 3 months.
After the dental evaluation and before admission for
HCT, 98.5% of patients had scaling and prophylaxis
completed. Therefore, the basic evaluation of obtaining
a full-mouth series and panoramic radiographs, clinical
evaluation, and completion of scaling and prophylaxis
cost $217 for patients on MassHealth dental insurance
and $293 for patients with private insurance.
Of the 405 patients in the study, 45.6% required
dental restorations, and 20.5% required at least one
extraction; 25% of patients required 1 to 2 restorations,
and 20.5% required 3 or more restorations (Figure 1).
Only 5% required endodontic therapy, and for those
with nonrestorable teeth, >90% required no more than
2 dental extractions. For <$500, 318 (78.9%) patients
and 275 (68.2%) patients under Medicaid reimburse-
ment and private dental insurance reimbursement,
respectively, could have had all their dental treatment
completed. For <$1000, the number of patients was
391 (96.5%) and 358 (88.3%), respectively (Figures 2
and 3).
The median and average costs of dental treatment
needed before HCT were $275 and $384, respectively,
based on MassHealth reimbursement and $368 and
$522, respectively, based on the “usual and customary”
fees for patients with private dental insurance (Table II).
The risk of streptococcal bacteremia in this pop-
ulation has been reported to be approximately
18%.5,8,28 If dental screening and treatment reduced the
risk among Medicaid beneﬁciaries by 25% (from 18%
to 11%), the dental interventions would have resulted
in cost savings (Figure 4). However, assuming a risk ofbacteremia of 5%, monetary savings would accrue only
in the case where risk was reduced by 75%. In the case
of commercial insurance, the thresholds are slightly
higher, owing to the higher costs of dental screening
and treatment. Nevertheless, assuming a baseline risk of
bacteremia of 18%, small cost savings would be
accrued, with risk reductions more than 25% (to about
11%) and savings exceeding $500 per patient if risk
was reduced by about half (from 18% to 7%;
Figure 5).
DISCUSSION
There are very few studies published on dental needs in
patients preparing for HCT. In this study, 45.6% of
patients needed restorations, and 20.5% needed at
least one extraction to treat active disease. In a study
by Vaughan et al. in the pediatric population, the prev-
alence of caries was 23%, and this lower number is to be
expected compared with adults.29,30 Our ﬁgures are
slightly lower than those reported by Graber et al.,31 who
found that 31 of 42 (67%) presented with dental caries,
whereas 47% needed at least one extraction. Akintoye
et al.28 reported that 35.1% and 41.6% required operative
procedures and extraction, respectively.
Studies indicate that the incidence of bacteremia
varied from 22.0% to 55.8% in all HCT patients.20,32,33
Bacteria may gain access to the patient’s bloodstream
through chemotherapy-induced ulcerative stomatitis
or from foci of dental infection. Patients are particu-
larly susceptible to viridans streptococcal infection
during the pre-engraftment phase, when patients are
profoundly neutropenic.15,34 Almyroudis et al.34 found
that patients with gram-positive bacterial septicemia (of
which 22% had viridans streptococci) had a signiﬁ-
cantly higher mortality rate and a lower 1-year survival
rate than those without septicemia. Similarly, Akintoye
et al. demonstrated that during the ﬁrst 100 days after
therapy, 34.8% of the study subjects had positive blood
cultures associated with clinical signs of septicemia;
46.9% of cultures were positive for streptococcal
bacteria, and, more speciﬁcally, 28.6% of cultures were
positive for Streptococcus mitis.28 Because viridans
streptococci play an important role in bacteremias,
a reduction in the number of these organisms in the
mouth may reduce the risk of septicemia. One way to
accomplish this is by restoring patients to dental health.
However, it should be borne in mind that while such
streptococci are predominantly inhabitants of the mouth
in humans and animals, they may also be isolated from
other anatomic organs, including the gastrointestinal
and genitourinary tracts.
Based on this study, the average cost to the payer of
dental treatment needed before HCT to restore the
patient to good dental health was $384 per patient,
based on MassHealth reimbursement, or $522 per
Fig. 1. Dental procedures needed to remove active disease before hematopoietic cell transplantation.
Fig. 2. The average dental cost per patient to treat active disease before hematopoietic cell transplantation. The cost for each patient
(n ¼ 405) was calculated at both MassHealth (Massachusetts Medicaid program) and private insurance reimbursement rates. The
median fees for private practice in the Boston area have been adjusted to 2012 levels.
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patients with private dental insurance. This cost is
minor compared with the overall costs of HCT (autol-
ogous or allogeneic) and the costs for identifying and
preparing a donor for allogeneic HCT. The median cost
for allogeneic HCT for myeloablative and reduced-
intensity conditioning HCT are $89,369 (range,
$66,894-$130,590) and $21,673 (range, $17,463-
$25,929) respectively.35 The mean cost for autologous
HCT has been reported to be $51,312.32
For our analysis, we assumed that the monetary cost
of treating patients with HCT who become septic isapproximately $14,399 for a 3-day hospital stay.
However, this cost is probably a low estimate. Jarvis
reported that even minimally effective infection control
programs are cost effective, because the average hospital
stay for bloodstream infections is 7 to 21 days, and the
average cost was between $3000 and $40,000 in 1996.33
Al-Rawajfah et al.36 reported that the average hospital
stay for bloodstream infections was 16 days, with an
average cost of approximately $85,000 in 2010, which
was $20,000 more than the average in 2003.
Treatment of active dental disease in patients in
preparation for HCT does not entail ideal, complex, or
Fig. 3. The cost distribution for dental treatment in the hematopoietic cell transplantation cohort of patients before transplantation.
All patients (n ¼ 405) were included in this ﬁgure twice to show the cost distribution for the same dental procedures suggested by
MassHealth and private insurance.
Table II. The cost of each dental treatment provided for adults, dictated by MassHealth and private dental insurance
Procedure MassHealth (US dollars)
Median (commercial) Boston
(US dollars)
Basic ﬁrst clinical
examination
$37 $47.99
Full-mouth radiograph series $69 $92.91
Panoramic ﬁlm $62 $85.21
Scaling and prophylaxis $49 $67.27
Single surface amalgam $58 $75.35
Two-surface amalgam $72 $94.95
Three-surface amalgam $86 $112.11
Endodontic treatment,
anterior
$375 $599.43
Endodontic treatment,
posterior
$569 $871.12
Single extraction $70 $94.95
Second extraction Single extraction cost 2 Single extraction cost 2
Anterior crown $499 $770.14
Posterior crown $499 $770.14
MassHealth, the Medicaid program in Massachusetts.
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incidence of infection during the period of neutropenia.
For the most part, the treatment plans for our patients
consisted of scaling and prophylaxis, restorative
dentistry, dental extractions, and root canal therapy, and
they generally did not include placement of crowns,
dental implants, or ﬁxed prosthetics; they also did not
include surgical periodontal treatment, unless such
therapy had already been started before the evaluation.
In this study, only 11 (2.7%) crowns were placed and
included in the analysis.
One of the limitations of this study is the retrospec-
tive nature of the data. The data are cross-sectional and
do not include the actual treatment that each patientreceived, because in a small number of cases, patients
were admitted before the procedures could be
completed. The examinations were done by many
different dentists in different states, although most were
in Massachusetts or the New England area. Differences
in diagnostic skills may vary, but having the dentists at
our hospital reevaluate the radiographs and discuss
complex cases with the dentist helps to provide some
uniformity in the treatment plan. Furthermore, the
reimbursements provided here are based on dental plans
in Massachusetts and would not necessarily apply to
other states. Nevertheless, these are fairly routine
procedures, and the reimbursements should not vary
substantially.
Fig. 5. Relationship between risk reduction for varying baseline risks of streptococcal bacteremia from dental treatment before
hematopoietic cell transplantation and average cost per patient (for patients with private insurance).
Fig. 4. Relationship between risk reduction for varying baseline risks of streptococcal bacteremia from dental treatment before
hematopoietic cell transplantation and average cost per patient (for MassHealth patients).
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that the rate of bacteremias in a cohort of patients that
were restored to optimal dental health would be lower
than in those who did not receive dental care. This
would entail performing a randomized controlled
clinical trial in which one group would receive dental
treatment and another no dental treatment, with
obvious ethical issues. It is also difﬁcult to determine
whether bacteremia in and of itself predicts increased
length of hospital stay. Nevertheless, dental evaluation
to optimize dental health before HCT is in keeping
with the overall context of other pre-HCT testing,
which includes pulmonary, cardiovascular, metabolic,
and other as-needed evaluations. As noted above, the
median dental treatment costs are minimal compared tooverall HCT costs. Finally, the estimated cost for an
extra 3-day stay in the hospital is probably a low
estimate, considering the cost of professional care in
an intensive care unit, pain medications and antibiotics,
laboratory testing, and nutritional support, even
without taking into account the morbidity suffered by
the patient.
If we assume that providing dental treatment for
patients before HCT may reduce infectious events
during the admission for HCT, it is likely to also lead to
improved quality of life, reduced length of hospital
stay, and reduced use of antibiotics. The expert care
provided by a dental specialist before HCT may thus
have a substantial impact on reducing the overall cost of
medical care.
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Septicemia results in signiﬁcant morbidity for patients
who undergo HCT, and the oral cavity is a reservoir for
gram-positive bacteria, which are common pathogens in
such septicemias. Because dental infection is a potential
source of septicemia, a dental evaluation to identify
such sources of infection may be an economical way to
reduce or prevent septicemia from an oral source when
patients are neutropenic. For less than $1000 in the state
of Massachusetts, dental needs for patients can be met
in more than 88% of patients, whether they are insured
under a government program or have private dental
insurance, and such care may result in less septicemia
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